Efferent Labs Applauds FDA's Shift Away from Animal Testing
Efferent Labs' CytoComm® platform is positioned as a critical enabler of new drug evaluation standards following the FDA's shift from animal testing.
'Our CytoComm® platform provides the dynamic cell-based insight and continuous real-time wireless feedback that traditional animal models simply cannot deliver.'— Bill Rader, CEO Efferent Labs
MOUNT PLEASANT, SC, UNITED STATES, April 17, 2025 / EINPresswire.com / -- Efferent Labs, Inc., a preclinical-stage biodevice company specializing in in vivo cellular data collection, celebrates the U.S. Food and Drug Administration's ( FDA ) groundbreaking move toward reducing reliance on mandatory animal testing for monoclonal antibody therapies and other drug classes. The long-awaited regulatory transformation serves to streamline development and improve patient outcomes and safety, while ultimately lowering costs.
The FDA's plan outlines a strategic shift toward New Approach Methodologies (NAMs) and positions Efferent Labs' revolutionary CytoComm® biosensor platform to support the transition with a human-relevant, wireless, real-time alternative that aligns directly with the FDA's roadmap.
'This is the moment we've been building toward,' said Bill Rader, CEO of Efferent Labs. 'Our CytoComm® platform provides the dynamic cell-based insight and continuous real-time wireless feedback that traditional animal models simply cannot deliver. With today's FDA announcement, Efferent Labs moves from visionary to essential.'
The FDA's pivot to AI-based toxicity and efficacy modeling relies on one critical factor: biologically meaningful, statistically reliable and clinically relevant inputs. However, many preclinical systems fall short of this standard.
The CytoComm® platform addresses these limitations by capturing continuous molecular activity from engineered cell lines in vivo. This enables clean, longitudinal data that supports earlier decision-making, reduces animal use, and improves predictive accuracy—all while laying the foundation for AI modeling that regulators can trust.
CytoComm® directly addresses the FDA's key aims under its new framework:
Reduces animal use by replacing live models with embedded, human-relevant cellular sensors
Accelerates development timelines via continuous real-time monitoring
Improves predictive accuracy by capturing complex pharmacodynamic data
Seamlessly integrates with AI workflows, supported by HookeCA™—Efferent's cloud-based analytics interface, which enables real-time data visualization and regulatory-aligned formatting
As the first implantable cellular biosensor of its kind, CytoComm® provides continuous, high-fidelity molecular data without relying on terminal endpoints or high-stress procedures. This enables researchers to capture detailed pharmacodynamic responses using smaller cohorts, fewer animals, and statistically robust outputs.
'We are proud to be part of the solution,' said Rader. 'The science is ready. The technology is here. And with this regulatory shift, the path is now clear. CytoComm® isn't just the future—it's the answer.'
For more information or partnership inquiries, visit http://www.efferentlabs.com
About Efferent Labs
Efferent Labs is pioneering the future of preclinical drug testing with its real-time cellular biosensor platform, CytoComm® Designed to replace static animal-based endpoints, CytoComm® delivers dynamic, high-fidelity cell-based insights—saving time, reducing costs, and elevating both human safety and ethical standards.
Kerry Welch
TRIO
+1 8084290548
email us here
Visit us on social media:
Facebook
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Built for America: GE Appliances Completes $180 Million Expansion at Georgia Plant
Latest milestone brings total investment in U.S. manufacturing to $3.5 billion since 2016 LAFAYETTE, Ga., June 11, 2025 /PRNewswire-PRWeb/ -- GE Appliances, a Haier company, today announced the completion of an expanded $180 million investment at its Roper Corporation cooking products plant in LaFayette, Georgia underscoring the company's Built for America commitment to U.S. manufacturing and delivering innovation to American homes. This investment includes an additional $60 million above the previously announced total. Since 2016, GE Appliances – currently rated America's #1 Appliance Company* – has invested over $3.5 billion in new technology and products across its U.S. operations, more than any other competitor. "At GE Appliances, we're investing in American manufacturing – right here in Georgia," said Luther Ingram, executive director and plant manager at Roper Corporation. "By combining advanced automation with the skills and dedication of our local team, we're creating high quality jobs, launching breakthrough products, and ensuring that 'Georgia Made' ranges are being shipped to homes across the country." This investment has enabled the purchase of state-of-the-art equipment, expanded production capacity, and accelerated the launch of innovative new products—most notably the new GE Profile™ induction range, a more accessible and affordable way for consumers to experience induction cooking. The plant's new, high-volume production lines can produce gas, electric, or induction ranges and flex to meet customer demand. New assembly lines feature advanced manufacturing technology, including robotic cells that assemble glass cooktops, program control boards, and rotate units for easier final assembly. Robotics use has more than tripled at Roper, improving efficiency and employee ergonomics. Workforce development programs, including robotics training for employees, are funded in part by a state grant and delivered in partnership with Georgia Northwestern Technical College. The combined investment has added more than 600 new jobs to the plant. "Investments by manufacturers such as GE Appliances at Roper Corporation are a major reason why Georgia boasts a gross regional product (GRP) of $678.2 billion, the 8th highest among U.S. states," said Lloyd Avram, president and CEO for the Georgia Association of Manufacturers. "Georgia's manufacturing sector, employing 426,940 production workers, is responsible for $77 billion of that output." Employment and Investment Impact in Georgia In 2024 alone, GE Appliances spent $235 million with 359 Georgia suppliers, and the company employs 2,650 people in Georgia. GE Appliances' operations, employees and suppliers have a $3 billion impact on Georgia's Gross Domestic Product (GDP), and they have contributed to the creation of 7,500 additional jobs in the state. Opened in 1973, Roper Corporation is the largest employer in Walker County, and one of the largest employers in northwest Georgia. The plant has 15 production lines that produce cooktops, wall ovens and ranges under the Monogram™, Café™, GE Profile™, and GE® brands. The plant is vertically integrated encompassing stamping, paint, enamel, welding, graphics and production – all under one roof. GE Appliances and Roper Corporation are proud participants in the Georgia Department of Economic Development's Georgia Made Program, an initiative that promotes and supports businesses that manufacture products within the state. In 2023, GE Appliances and Roper Corporation celebrated the plant's 50-year legacy of cooking product innovation and dedication to quality and dependability. "Our growth in LaFayette reflects Georgia's vital role in driving U.S. manufacturing forward," Ingram added. "We're not just building appliances—we're building careers, strengthening communities, and powering the future of American industry." About GE Appliances At GE Appliances, a Haier company, we come together to make good things, for life. Headquartered in Louisville, Kentucky, we are a leading U.S. manufacturer of home appliances with 15,500 team members nationwide. GE Appliances, found in half of all U.S. homes, is proud to be rated America's #1 Appliance Company*, trusted by millions of families nationwide. We manufacture and sell products under the Monogram™, Café™, GE Profile™, GE®, Haier™, and Hotpoint™ brands. Our operations support nearly 98,000 additional American jobs and represent an investment of more than $3.5 billion since 2016. We are deeply committed to the communities where we live and work, passionate about getting closer to our product users to understand their needs and driven by the belief that there's always a better way. To learn more about our company, brands, career opportunities, and impact, visit or connect with us on LinkedIn. *OpenBrand Consumer Tracking Survey, Q1 – Q4 2024, Based on Volume of Total Majors/MO/RAC – Retail Units Media Contact Dawn Bramblett, Bramblett Group, 731-608-7650, dawn@ View original content to download multimedia: SOURCE Bramblett Group Sign in to access your portfolio
Medscape
39 minutes ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
Yahoo
an hour ago
- Yahoo
C Spire Named 2025 Southeast Partner of the Year by Arctic Wolf
Ridgeland-based Business Receives Honor from Global Leader in Security Operations RIDGELAND, Miss., June 11, 2025--(BUSINESS WIRE)--C Spire has been named Arctic Wolf Southeast Partner of the Year for 2025. This recognition highlights the company's exceptional leadership in cybersecurity, outstanding service delivery, and commitment to helping mutual customers drive innovation and achieve stronger security outcomes. "We are honored to be recognized as Arctic Wolf Southeast Partner of the Year and look forward to delivering even more cybersecurity innovation and value for our customers," said Drake Cushing, Senior Vice President and General Manager for C Spire Business. "Cybersecurity threats and their constant advancement in attack methods continue to grow and require forward-focusing technology to protect businesses. Through our partnership with Arctic Wolf, C Spire continues to deliver advanced technology our customers need and expect from us." The Arctic Wolf Partner of the Year Awards recognize elite partners who have demonstrated outstanding leadership in helping organizations improve their security operations through Arctic Wolf's portfolio of solutions. Now in their eighth year, the honors celebrate top-performing companies that have shown excellence in security practice, executive alignment, revenue growth, and service. "This year's award winners represent the very best of the Arctic Wolf partner community," said Will Briggs, Senior Vice President, Global Channels, Arctic Wolf. "Each of these organizations has demonstrated exceptional commitment to our shared mission to end cyber risk, helping customers navigate an increasingly complex threat landscape with confidence and resilience. We're proud to recognize their achievements and celebrate the critical role they play in driving meaningful security outcomes." C Spire Business is a division of C Spire, a diversified telecommunications and technology services provider. C Spire has highly certified IT engineering talent in markets across the Southeast U.S. and specializes in connecting businesses of all sizes with best-in-class solutions. Cloud, collaboration, cybersecurity, managed IT, fiber connectivity — C Spire Business delivers all the power and expertise organizations need to win. As organizations worldwide face an increasingly complex threat landscape and a persistent cybersecurity talent shortage, over 10,000 organizations globally now rely on the Arctic Wolf Aurora Platform to help end cyber risk. Built on an open-XDR architecture and powered by Alpha AI™ technologies, the Aurora Platform is designed to deliver positive security outcomes at scale. Each week, it ingests, parses, enriches, and analyzes over eight trillion security events—transforming overwhelming volumes of data into an average of just one actionable alert per customer per day. Additional Resources For more information about C Spire, visit For more information about Arctic Wolf, please visit About C SpireC Spire is a diversified telecommunications and technology services company that provides a full suite of dedicated internet, wireless, IP Voice, data, cloud and managed IT services for businesses and enterprises, world-class, customer-inspired wireless communications, as well as fiber internet for consumers. This news release and other announcements are available at For more information about C Spire, visit or follow us on Facebook at or X at View source version on Contacts Press Contact C SpireCourtney Grimes, 601-746-2737cgrimes@
